Our company attended the CPHI exhibition in Madrid, Spain

From October 2 to October 4 in 2007, with the purpose of further promoting our overseas markets and finding some cooperative customers, Mr. ZHOU Li, Director of Overseas Marketing and his assistant, Mr. LIN Wei attended the CPHI in Madrid, Spain. We received nearly 60 customers and had in-depth discussions with them. Through our effort, the relationship with overseas customers was explored and strengthened. During the exhibition, many companies showed favorable interests in our products, some of them even placed orders on site. Currently we are in negotiation with the customers.

 

Enoxaparin sodium PFS (Pre-filled Syringe) is approved for marketing in China

In April 2006, enoxaparin sodium PFS, a new medicine developed by our company, was approved for manufacturing and marketing by Registration Bureau of State Food and Drug Administration (SFDA). Enoxaparin sodium is a low molecular weight heparin (MW approx. 4500 D) obtained by controlled depolymerisation of a benzyl ester of natural heparin. Enoxaparin sodium is indicated for:
1. Prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery.
2. Prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness.
3. Prevention of thrombosis in extra-corporeal circulation during haemodialysis.
4. Treatment of established deep vein thrombosis.
5. Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.
We are promoting it in domestic and international markets now.